华蟾素联合TACE治疗原发性肝癌临床观察

Clinical observation of Cinobufacini injection combined with TACE in the treatment of hepatocellular carcinoma

关键词:  华蟾素  经肝动脉化疗栓塞  原发性肝癌  疗效观察

Key words:  Cinobufacini injection  TACE  hepatocellular carcinoma  observation of efficacy

摘要:

[目的] 观察华蟾素联合经动脉灌注化疗栓塞术(TACE)治疗原发性肝癌的临床疗效及安全性。[方法] 以2011年1月-2013年2月于本院住院治疗的患者53例为研究对象,随机分为对照组和治疗组。其中对照组27例,单纯给予TACE治疗;治疗组26例,在TACE治疗的基础上,联用华蟾素注射液治疗。比较两组患者(AFP)、肿瘤客观大小、生活质量(KPS评分)、中医证候积分及术后不良反应。[结果] 对照组剔除2例,治疗组剔除1例。与对照组相比,治疗组AFP下降较显着,差异有统计学意义(P<0.05).分析肿瘤客观大小得出治疗组与对照组疾病控制率分别为88.00%(22/25)和79.17%(19/24),差异有统计学意义(P<0.05).在提高患者生活质量、改善中医证候方面,治疗组明显优于对照组,差异有统计学意义(P<0.05).观察肝功能损伤、骨髓抑制、消化道不良反应的发生,治疗组明显低于对照组(P<0.05).[结论] 华蟾素与TACE联用治疗原发性肝癌,显着降低AFP水平,提高治疗肿瘤的疾病控制率,缓解临床症状,提高患者生活水平,并减少不良反应的发生,具有减毒增效的作用。

Abstract:

[Objective] To define the safety and effect of combination of Cinobufacini injection and transcatheter arterial chemoembolization(TACE) in patients with hepatocellular carcinoma. [Methods] The 53 cases of hepatocellular carcinoma were selected and randomly assigned into control group and treatment group. Patients of control group(27 cases) received TACE treatment only, while others of treatment group(26 cases) received Cinobufacini injection as well as TACE treatment. The AFP, objective tumor size, quality of life score, symptom score of traditional Chinese medicine and toxicity were assessed. [Results] Two cases were removed in control group and treatment group excluded one case. In treatment group AFP decreased significantly than control group (P<0.05). Disease control rate was 88.00%(22/25) in treatment group and 79.17%(19/24)in control group, which showed significant difference between two groups(P<0.05). Quality of life score and symptom score of traditional Chinese medicine were improved and showed better results in treatment group than those observed in control group(P<0.05). The incidence of liver toxicity, marrow suppression and gastrointestinal reaction was significantly lower than that in the control group(P<0.05). [Conclusion] The combination of Cinobufacini injection and TACE in treatment of hepatocellular carcinoma can significantly decrease AFP, improve disease control rate, relieve clinical symptoms, improve life quality of patients and reduce the incidence of adverse reactions.